Scarica l'app Stockscreener
5.19
7.34%
0.355
Dopo l'orario di chiusura:
5.19
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NXTC Giù?
Forum
Previsione
Precedente Chiudi:
$4.835
Aprire:
$4.81
Volume 24 ore:
27,849
Relative Volume:
0.11
Capitalizzazione di mercato:
$13.89M
Reddito:
-
Utile/perdita netta:
$-58.52M
Rapporto P/E:
-2.4833
EPS:
-2.09
Flusso di cassa netto:
$-45.03M
1 W Prestazione:
+0.58%
1M Prestazione:
+1,214%
6M Prestazione:
+616.26%
1 anno Prestazione:
+224.38%
Intervallo 1D:
$4.81
$5.23
Intervallo di 1 settimana:
$4.75
$5.42
Portata 52W:
$0.224
$6.42
Nextcure Inc Stock (NXTC) Company Profile
Nome
Nextcure Inc
Settore
Industria
Telefono
240-399-4900
Indirizzo
9000 VIRGINIA MANOR ROAD, SUITE 200, BELTSVILLE, MD
Confronta NXTC con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NXTC
Nextcure Inc
|
5.19 | 12.94M | 0 | -58.52M | -45.03M | -2.09 |
|
VRTX
Vertex Pharmaceuticals Inc
|
395.92 | 99.42B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.55 | 58.99B | 14.21B | 4.46B | 3.56B | 39.68 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.52 | 56.35B | 2.46B | -319.09M | -52.09M | -2.47 |
|
ARGX
Argen X Se Adr
|
646.60 | 39.02B | 3.06B | 1.28B | -614.78M | 21.30 |
|
ONC
Beone Medicines Ltd Adr
|
307.51 | 34.25B | 3.81B | -644.79M | -669.77M | -6.24 |
Nextcure Inc Stock (NXTC) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2022-11-04 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| 2022-03-01 | Iniziato | Ladenburg Thalmann | Buy |
| 2021-03-05 | Aggiornamento | Truist | Hold → Buy |
| 2021-01-15 | Downgrade | BofA Securities | Neutral → Underperform |
| 2020-07-16 | Aggiornamento | The Benchmark Company | Hold → Buy |
| 2020-07-13 | Downgrade | ROTH Capital | Buy → Neutral |
| 2020-07-13 | Downgrade | SunTrust | Buy → Hold |
| 2020-06-01 | Downgrade | BofA/Merrill | Buy → Neutral |
| 2020-06-01 | Downgrade | The Benchmark Company | Buy → Hold |
| 2020-05-26 | Iniziato | JMP Securities | Mkt Outperform |
| 2020-03-24 | Iniziato | The Benchmark Company | Buy |
| 2020-03-02 | Iniziato | ROTH Capital | Buy |
| 2020-01-13 | Iniziato | SunTrust | Buy |
| 2019-12-05 | Iniziato | Needham | Buy |
| 2019-11-26 | Iniziato | BTIG Research | Buy |
| 2019-07-09 | Iniziato | BofA/Merrill | Buy |
| 2019-06-03 | Iniziato | Morgan Stanley | Overweight |
| 2019-06-03 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Nextcure Inc Borsa (NXTC) Ultime notizie
Visualizing NextCure Inc. stock with heatmapsJuly 2025 Short Interest & Accurate Buy Signal Alerts - Newser
NextCure Inc. stock prediction for this weekWeekly Investment Recap & Weekly Breakout Stock Alerts - Newser
Using fundamentals and technicals on NextCure Inc.Market Performance Summary & Consistent Profit Focused Trading Strategies - Newser
Technical signs of recovery in NextCure Inc. [Rate Hike]Free Safe Investment Capital Preservation Plans - Newser
Technical signs of recovery in NextCure Inc.Technical Setup and Return Forecast Engine - Newser
NextCure Inc. stock volume spike explained2025 Growth vs Value & Risk Managed Investment Entry Signals - Newser
Will NextCure Inc. stock recover after recent dropTechnical Confirmation System with Signal Alerts - Newser
What makes NextCure Inc. stock price move sharplyFree High Accuracy Alerts for ROI Traders - Newser
Does NextCure Inc. qualify in momentum factor screeningFree Consistent Income Focused Trade List - Newser
Why NextCure Inc. stock attracts strong analyst attentionFree Accurate Technical Trend Reversal Picks - Newser
Backtesting results for NextCure Inc. trading strategiesFree Short Term Trading Opportunity Watch - Newser
Published on: 2025-08-11 00:58:31 - Newser
How to monitor NextCure Inc. with trend dashboardsStock Forecast Tools for Retail Traders - Newser
How NextCure Inc. stock performs during market volatilityCapital Secure Pattern Signal Analysis Sheet - Newser
NextCure Inc. Company Revenue and Profit Trends: A Deep DiveMomentum Stocks with Breakout Potential - Newser
Is it time to cut losses on NextCure Inc.Early Entry Ideas with Momentum Potential - Newser
NextCure Inc. Earnings Report Breakdown: What Investors Should KnowConservative Investment Setup and Risk Analysis - Newser
Analysts Offer Insights on Healthcare Companies: Avalo Therapeutics (AVTX), Iovance Biotherapeutics (IOVA) and NextCure (NXTC) - The Globe and Mail
NextCure Reports Q2 2025 Earnings, Partners with Simcere Zaiming, and Advances Clinical Trials - AInvest
NextCure (NXTC) Q2 Loss Widens 71% - AOL.com
NextCure Reports Q2 2025 Results and Strategic Updates - TipRanks
NextCure Inc reports results for the quarter ended June 30Earnings Summary - TradingView
NextCure (NXTC) Q2 Loss Widens 71% - The Motley Fool
NextCure Provides Business Update and Reports Second Quarter 2025 Financial Results - The Manila Times
NextCure's Dual ADC Cancer Programs Progress: Strategic Partnership Fuels Clinical Advancement - Stock Titan
Short interest data insights for NextCure Inc.Long-Term Investment Strategy Impact Analysis - Newser
Fibonacci Support Holding Strong in NextCure Inc.Swing Trade Plans Emphasize Risk Management - beatles.ru
What indicators show strength in NextCure Inc.Free Low Risk Picks for Daily Trading - Newser
What are the latest earnings results for NextCure Inc.Superior risk-adjusted returns - Jammu Links News
When is NextCure Inc. stock expected to show significant growthRapidly expanding wealth - Jammu Links News
What drives NextCure Inc. stock priceBreakthrough stock performance - Jammu Links News
Published on: 2025-08-03 14:04:52 - Jammu Links News
Is it the right time to buy NextCure Inc. stockBuild a diversified portfolio for risk mitigation - Jammu Links News
How does NextCure Inc. generate profit in a changing economyTremendous return rates - Jammu Links News
Nextcure Inc Azioni (NXTC) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.67%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):